Xoma Technology Ltd.

Xoma (us) LLC

Second Genome, Inc.

Musc Foundation for Research Development

Pfizer Corporation

Schering Corporation

Bayer Corporation

Bayer Pharmaceutical Corporation

Bioren, Inc.

Toshihiko Takeuchi

Daniel H Bedinger

Amer M Mirza

Shireen S Khan

Ajay J Narasimha

Kirk William Johnson

Hassan Issafras

Kiranjit Kaur Ahluwalia

Agnes Choppin Holmes

Andrew Wonhee Han

Karim Dabbagh

Ye Jin

Ou Li

Andrew Whitman Goodyear

Tarunmeet Gujral

Stefanie Banas

Raphael D Levy

Michi Izumi Willcoxon

Marina Roell

Mark Rubinstein

Rachel A Hunt

Robyn Cotter

Hoa Giang

Todd Zachary Desantis

Lauren Schwimmer

Kristin Camfield Lind

Llewelyn Lao

Arvind Rajpal

Roberto Crea

Linda Masat

John Corbin

John E Murphy

Randy Shen

Sumant Ramachandra

Guido Cappuccilli

Chin-Yi Huang

Todd Zachary DeSantis

Nathalie Dubois-Stringfellow

Chao Bai Huang

Walter Robert Bishop

Chung-Leung Chan

Julie Rinkenberger

Seema Kantak

Paul Rubin

Ira Goldfine

Adrian Tomkinson

Steven Neben

Raphael David Levy

Nurten Bayez

Guido Cappucilli

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.

Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment

The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.

Universal antibody libraries

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Proteins for the treatment of epithelial barrier function disorders

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF&#x3b2;), including TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF&#x3b2; expression.

Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3

Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-&#x3b2;

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.

Methods and materials for enhancing functional protein expression in bacteria

TGF-beta-specific antibodies and methods of use thereof for treatment

Antibodies specific for TGF-&#x3b2;  and methods of treatment thereof

Growing community of inventors

Oakland, CA, United States of America

Toshihiko Takeuchi